Abstract
Vasopeptidase inhibitors are a novel class of antihypertensive agents that concomitantly inhibit angiotensin converting enzyme and neutral endopeptidase. Our purpose was to investigate the effects of omapatrilat, a vasopeptidase inhibitor, on renal function and tubuloglomerular feedback (TGF) response in anesthetized 9–10-week-old spontaneously hypertensive rats (SHR). Intravenous injection of omapatrilat at 10 μmol/kg decreased systemic blood pressure and renal vascular resistance. Renal plasma flow was unchanged, whereas glomerular filtration rate (GFR) and filtration fraction (FF) were reduced. Increased urinary sodium excretion of tubular origin was observed. These parameters remained unaltered with vehicle treatment. Micropuncture study revealed that the maximal reduction of early proximal flow rate (EPFR) induced by orthograde perfusion of Henle's loop with artificial tubular fluid (ATF) was significantly reduced by omapatrilat treatment (28.5 ±3.1% vs. 72.0±2.8% of control) and was not significantly changed in the vehicle-treated group (vehicle 70.8±1.7% vs. control 71.0 ±2.1%). EPFR at zero perfusion was comparable between omapatrilat and vehicle treatment (29.7±2.2 vs. 31.3 ±2.1 nl/min, respectively). Luminal perfusion of 10-4 mol/l 7-nitroindazole in ATF abrogated the blunting of TGF response by omapatrilat but elicited no change in the vehicle-treated group. The suppression of the TGF mechanism and the reduction in FF suggest that omapatrilat respectively dilates the afferent and efferent arterioles. Under such conditions, reduction of GFR may indicate a fall in intraglomerular pressure. The restoration of nitric oxide signaling in the juxtaglomerular apparatus of SHR seems to participate in the inhibition of TGF by omapatrilat. These findings suggest that omapatrilat may provide a novel approach to the treatment of systemic and glomerular hypertension.
Similar content being viewed by others
Article PDF
References
Weber M : Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens 1999; 12: S139–S147.
Corti R, Burnett JC, Rouleau JL, Ruschitzka F, Luscher TF : Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease ? Circulation 2001; 104: 1856–1862.
Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR : Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998; 11: 363–372.
Groholm T, Finckenberg P, Palojoki E, et al: Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet. Hypertens Res 2004; 27: 609–618.
Campese VM, Lasseter KC, Ferrario CM, et al: Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2001; 38: 1342–1348.
McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG : The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 479–486.
Schnermann J : Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 1998; 274: R263–R279.
Dilley JR, Stier CT Jr, Arendshorst WJ : Abnormalities in glomerular function in rats developing spontaneous hypertension. Am J Physiol 1984; 246: F12–F20.
Takabatake T, Ushiogi Y, Ohta K, Hattori N : Attenuation of enhanced tubuloglomerular feedback activity in SHR by renal denervation. Am J Physiol 1990; 258: F980–F985.
Brannstrom K, Morsing P, Arendshorst WJ : Exaggerated tubuloglomerular feedback activity in genetic hypertension is mediated by ANG II and AT1 receptors. Am J Physiol 1996; 270: F749–F755.
Kovacs G, Komlosi P, Fuson A, Peti-Peterdi J, Rosivall L, Bell PD : Neuronal nitric oxide synthase: its role and regulation in macula densa cells. J Am Soc Nephrol 2003; 14: 2475–2483.
Thorup C, Persson AE : Impaired effect of nitric oxide synthesis inhibition on tubuloglomerular feedback in hypertensive rats. Am J Physiol 1996; 271: F246–F252.
Persson AE, Gutierrez A, Pittner J, et al: Renal NO production and the development of hypertension. Acta Physiol Scand 2000; 168: 169–174.
Haberle DA, Davis JM, Kawabata M, Metz C, Wapler P, Stachl M : Renal and single-nephron function is comparable in thiobutabarbitone- and thiopentone-anaesthetised rats. Pflügers Arch 1993; 424: 224–230.
Seymour AA, Mathers P : BMS 186, 716 in conscious sodium replete monkeys: effects on blood pressure, heart rate and renal function. Bristol-Myers Squibb Pharmacol Rep 1993; September 13.
Seymour AA, Asaad M, Mathers P : BMS 186, 716 in conscious sodium replete monkeys: urinary ANP and cyclic GMP excretion. Bristol-Myers Squibb Pharmacol Rep 1994; September 9.
Wolff DJ, Gribin BJ : The inhibition of the constitutive and inducible nitric oxide synthase isoforms by indazole agents. Arch Biochem Biophys 1994; 311: 300–306.
Welch WJ, Tojo A, Lee JU, Kang DG, Schnackenberg CG, Wilcox CS : Nitric oxide synthase in the JGA of the SHR: expression and role in tubuloglomerular feedback. Am J Physiol 1999; 277: F130–F138.
Ise T, Takabatake T, Ohta H, et al: Effects of atrial natriuretic polypeptide on renal microcirculation. Microcirculation Annu 1989; 5: 137–138.
Kawabata M : Effects of atrial natriuretic polypeptide on tubuloglomerular feedback. J Juzen Med Soc 1989; 98: 477–488 ( in Japanese).
Taal MW, Nenov VD, Wong WC, et al: Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 2001; 12: 2051–2059.
Zhou X, Ono H, Ono Y, Frohlich ED : Renoprotective effects of omapatrilat are mediated partially by bradykinin. Am J Nephrol 2003; 23: 214–221.
Schmitt F, Martinez F, Ikeni A, et al: Acute renal effects of neutral endopeptidase inhibition in humans. Am J Physiol 1994; 267: F20–F27.
Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE : Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001; 60: 715–721.
Benigni A, Zoja C, Zatelli C, et al: Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int 2004; 66: 1959–1965.
Massien C, Azizi M, Guyene TT, Vesterqvist O, Mangold B, Menard J : Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin Pharmacol Ther 1999; 65: 448–459.
Rousso P, Buclin T, Nussberger J, et al: Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers. J Hypertens 1999; 17: 427–437.
Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR : Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors. J Pharmacol Exp Ther 1996; 276: 708–713.
Zeidel ML : Renal actions of atrial natriuretic peptide: regulation of collecting duct sodium and water transport. Annu Rev Physiol 1990; 52: 747–759.
Davis CL, Briggs JP : Effect of reduction in renal artery pressure on atrial natriuretic peptide-induced natriuresis. Am J Physiol 1987; 252: F146–F153.
Seymour AA, Fennell SA, Swerdel JN : Potentiation of renal effects of atrial natriuretic factor-(99–126) by SQ 29,072. Hypertension 1989; 14: 87–97.
Motwani JG, Lang CC, Cramb G, Struthers AD : Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men. Hypertension 1995; 25: 637–642.
Inoue T, Nonoguchi H, Tomita K : Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. Cardiovasc Res 2001; 51: 470–480.
Schiltz JC, Hoffman GE, Stricker EM, Sved AF : Decreases in arterial pressure activate oxytocin neurons in conscious rats. Am J Physiol 1997; 273: R1474–R1483.
Gebremedhin D, Fenoy FJ, Harder DR, Roman RJ : Enhanced vascular tone in the renal vasculature of spontaneously hypertensive rats. Hypertension 1990; 16: 648–654.
Takabatake T, Ushiogi Y, Ise T, Kobayashi K : Effect of calcium antagonist, manidipine hydrochloride, on renal hemodynamics and tubuloglomerular feedback in spontaneously hypertensive rats. Am Heart J 1993; 125: 578–581.
Thomson SC, Bachmann S, Bostanjoglo M, et al: Temporal adjustment of the juxtaglomerular apparatus during sustained inhibition of proximal reabsorption. J Clin Invest 1999; 104: 1149–1158.
Ollerstam A, Pittner J, Persson AE, Thorup C : Increased blood pressure in rats after long-term inhibition of the neuronal isoform of nitric oxide synthase. J Clin Invest 1997; 99: 2212–2218.
Liao WC, Vesterqvist O, Delaney C, et al: Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects. Br J Clin Pharmacol 2003; 56: 395–406.
Schnermann J, Briggs JP : Interaction between loop of Henle flow and arterial pressure as determinants of glomerular pressure. Am J Physiol 1989; 256: F421–F429.
Moore LC : Tubuloglomerular feedback and SNGFR autoregulation in the rat. Am J Physiol 1984; 247: F267–F276.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, T., Takabatake, T. Effects of Vasopeptidase Inhibition on Renal Function and Tubuloglomerular Feedback in Spontaneously Hypertensive Rats. Hypertens Res 28, 611–618 (2005). https://doi.org/10.1291/hypres.28.611
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.611
Keywords
This article is cited by
-
Calcium channel blocker in patients with chronic kidney disease
Clinical and Experimental Nephrology (2022)
-
Novel Concepts in the Genesis of Hypertension: Role of LOX-1
Cardiovascular Drugs and Therapy (2011)
-
Strong suppression of the renin–angiotensin system has a renal-protective effect in hypertensive patients: High-dose ARB with ACE inhibitor (Hawaii) study
Hypertension Research (2010)